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Abstract
Anti-idiotype antibodies have potential therapeutic applications in many fields, including autoimmune diseases. Herein we
report the isolation and characterization of AIM2, an anti-idiotype antibody elicited in a mouse model upon expression of
the celiac disease-specific autoantibody MB2.8 (directed against the main disease autoantigen type 2 transglutaminase,
TG2). To characterize the interaction between the two antibodies, a 3D model of the MB2.8-AIM2 complex has been
obtained by molecular docking. Analysis and selection of the different obtained docking solutions was based on the
conservation within them of the inter-residue contacts. The selected model is very well representative of the different
solutions found and its stability is confirmed by molecular dynamics simulations. Furthermore, the binding mode it adopts is
very similar to that observed in most of the experimental structures available for idiotype-anti-idiotype antibody complexes.
In the obtained model, AIM2 is directed against the MB2.8 CDR region, especially on its variable light chain. This makes the
concurrent formation of the MB2.8-AIM2 complex and of the MB2.8-TG2 complex incompatible, thus explaining the
experimentally observed inhibitory effect on the MB2.8 binding to TG2.
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Introduction
It has been long established that the structural basis for antigen
(Ag) recognition by antibodies (Abs) relies on the length and
sequence variability of the six Ab complementary determining
regions (CDRs) [1]. Based on the combinatorial origin of this
limited region, made by about 70 residues, antibodies are able to
recognize almost an infinite variety of antigens, from small organic
molecules to proteins. Interestingly, antibodies can be antigenic
themselves, being recognized by other antibodies and thus creating
a network, through which immunoglobulins expression may be
controlled. According to the ‘‘idiotypic network hypothesis’’ [2],
under specific immunological conditions, antigen stimulation leads
to the production of idiotype antibodies (termed Ab1) against Ag,
characterized by specific antigenic-determinants (the ‘‘idiotopes’’).
The unique structure of the Ab1 antigen-binding site can generate
in turn the production of a series of anti-idiotype antibodies,
termed Ab2s, which are directed against the Ab1 antigenic-
determinants (Figure 1a) and may or may not represent an image
of the original Ag. Finally, anti-anti-idiotypes antibodies (Ab3s) can
be induced by the presence of Ab2, which may have binding
capabilities similar to those of Ab1, thus recognizing the original
antigen. An anti-idiotype antibody can be classified as: i) ‘‘Ab2-
alpha’’(Ab2a); ii) ‘‘Ab2-beta’’ (Ab2b); iii)‘‘Ab2-gamma’’ (Ab2c), on
the basis of their ability to inhibit the binding of Ab1 to the original
antigen (see Figure 1a) [3,4].
Several experimental evidences have demonstrated the crucial
role played by the idiotypic Ab1-Ab2-Ab3 network in the
regulation of immune response to both external and self antigens
[4,5]. In recent years, extensive research has been devoted to the
possible therapeutic application of anti-idiotype antibodies. Ab2s
have been the basis for developing new generation vaccines [6,7]
and novel therapeutic approaches for the treatment of tumours
[7,8], such as breast cancer [9,10], colorectal carcinoma [11],
melanoma and ovarian lymphoma [12,13]. They have also been
suggested for the design of anti-HIV strategies for AIDS [14,15]
and as potent anticoagulants to restore normal haemostasis [16].
The idiotypic network has also been shown to have a
fundamental role in the autoimmune diseases. While the factors
leading to the onset of the autoimmune response remain obscure,
the idiotypic disregulation is now indeed recognized as a major
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mechanism for autoimmunity [17–22]. Deficient idiotypic regu-
lation of autoantibodies has been considered a contributing factor
for a number of autoimmune diseases [22], such as systemic lupus
erythematosus (SLE) [19], autoimmune thyroiditis [17], systemic
vasculitis [18] and the Guillain-Barre` syndrome [21]. Further-
more, it has been demonstrated that autoimmune patients show a
large ratio of autoantibody to anti-idiotype concentration whereas
this ratio is small in healthy controls [20]. In vivo studies have
indicated that anti-idiotypic antibodies might be able to down-
regulate the autoantibodies, making the use of Ab2s very
promising in the study and treatment of autoimmune diseases.
In type 1 diabetes, for example, it has been recently shown that
anti-idiotypes may play a protective role in the immune response,
by preventing the autoantibody from binding its antigen [23].
Another intriguing application of Ab2 is in creating animal models
to study autoimmunity by inducing it in animals through the usage
of pathogenic idiotypes of autoantibodies. Following immunization
with Ab1 and production of Ab2s, the animals may also develop
Ab3s, having original autoantibodies properties and being
associated with the respective serological and clinical manifesta-
tions of the disease [4,24].
One of the most common diseases with autoimmune features
that suffers from a lack of animal models is celiac disease (CD). CD
is characterized by the presence of specific antibodies recognizing
an endomysial autoantigen identified as type 2 transglutaminase
(TG2) [25]. The antibody level against TG2 increases upon
Figure 1. Scheme of the idiotypic network and specificity of the AIM2 response. a) The idiotypic network. An antigen, Ag, is recognized by
its antibody Ab1. The Ab1 becomes itself an antigen eliciting the production of anti-antibodies Ab2. This response can be divided into: i) an antigen-
non inhibitable group (Ab2a), ii) an antigen-inhibitable group bringing an ‘‘internal image’’ of the antigen (Ab2b), and iii) an antigen-inhibitable
group due to steric hindrance with the antigen binding-site (Ab2c). b) Specificity of AIM2 response. Immunoreactivity of phage expressed AIM2 scFv
was tested by ELISA against MB2.8 (used for selection) and 3 others scFv-Fc. MB3.7 is a celiac-derived anti-TG2 antibody while MB6.2 and MBV5B2 are
control antibodies using the VH5 gene for VH Chain.
doi:10.1371/journal.pone.0102839.g001
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exposure to gluten, and decreases during the course of a gluten-
free diet [26]. We have recently [27] found clear evidence that a
specific anti-idiotypic response could be induced in mouse by
ectopically expressing an anti-TG2 antibody derived from CD
patients [28] and cross-reactive with the mouse protein. Further-
more, by ELISA assays, this response was able to compete with
immobilized TG2 antigen for anti-TG2 binding, suggesting a
binding restricted or close to the original antibody CDR region
[27].
Here we report the isolation and characterization of an anti-
idiotypic antibody that we named AIM2 (Anti-Idiotype Mouse 2)
from a mouse (mouse 2, in Di Niro et al. [27]) giving the highest
binding specificity towards the celiac autoantibody MB2.8
expressed in the same mouse. To characterize the interaction
between the anti-TG2 antibody (Ab1-MB2.8) and its anti-idiotype
(Ab2-AIM2), here we present the 3D model we obtained for the
MB2.8-AIM2 complex by docking simulations. We applied a new
protocol to the analysis and selection of representative decoys,
based on the conservation of inter-residue contacts at the interface
[29–33]. We have previously proposed intermolecular contact
maps (i.e. maps where a black dot is present at the crossover of two
interacting residues) as fingerprints of the interface in protein
complexes [29–31]. They report the crucial information in a
ready-to-read form and allow to easily and intuitively discriminate
between similar and different binding solutions [30]. Furthermore,
we have shown that intermolecular contact maps, together with
the measure of the conservation of inter-molecular contacts, can
be used to analyse docking model ensembles [29] and to reliably
extract from them the native-like solutions [31,32].
Interestingly, as a result of this analysis, a clearly-preferred
solution emerged, that we thoroughly characterized in its static
and dynamic features and compared with the six available
experimental structures of Ab1-Ab2 complexes [14,16,34–37].
Materials and Methods
Anti-idiotype single chain (sc) Fv isolation
The phage display Ab library used for selection was derived
from spleen lymphocytes isolated from mouse N.2 [27], previously
characterized to have an anti-idiotypic response to the in vivo-
expressed recombinant scFv-Fc MB2.8 specific for TG2. The
library was constructed according to standard procedure [38].
Panning was performed in immunotubes coated with human scFv-
Fc antibody MB2.8 by overnight incubation at 4uC as previously
reported [38]. The panning procedure was repeated twice. 96
random clones were selected and the phages from single colonies
were grown in 96-well plates. A positive clone (AIM2) was
identified by phage ELISA and the V genes was sequenced and
the VH and VL families, as well as the gene segments used, were
assessed by screening using the IMGT/V-QUEST tool in
theIMGT, the ImMunoGeneTics information system http://
imgt.cines.fr. The positive scFv AIM2 was converted into a scFv-
Fc format first by subcloning into the pMB-SV5 [39] vector
containing the human IgG1 Hinge-CH2-CH3 domain. The
recombinant antibody was finally subcloned into pUCOE vector
[40] for expression and purification.
Molecular modeling
Abs modeling. The variable domain structures of MB2.8 and
Ab2-mouse AIM2 were modeled by the RosettaAntibody Server
[41,42], using the default full refinement protocol option. The
PDB codes of the templates for Ab1 MB2.8, used in the
simulations, are as follows (sequence identity is indicated in
parentheses): 3NCJ for the heavy chain framework (95%) and
1T3F for the light chain (98%); 1DFB for L1 (100%), 1DFB for L2
(86%), 2NY4 for L3 (60%); 2H32 for H1 (90%), 2XWT for H2
(94) and no template for H3 (re-modeled de novo using a kinematic
loop modeling algorithm developed in a Rosetta protocol). The
PDB codes of the templates for Ab2 AIM2 are as follows (sequence
identity is indicated in parentheses): 1MH5 for the heavy-chain
framework (97%) and 1AY1 for the light chain (97%); 1AY1 for
L1 (100%), 1SEQ for L2 (100%), 1AY1 for L3 (78%); 1IQW for
H1 (90%), 1IQW for H2 (100%) and no template for H3 (re-
modeled de novo, see above). Length and canonical structures of
the loops, reported in Table 1, were assigned by DIGIT [43].
Molecular docking. The obtained models were then used for
Ab1/Ab2 protein-protein docking simulations, performed by the
ClusPro 2.0 server [44]. In all the simulations, the Ab2 residues
that did not fall into the CDRs were masked, using the ClusPro
Antibody Mode option [45]. Differently, for MB2.8 two situations
were explored. In the first one, indicated in the following as ‘CDR-
directed’, all residues but the CDR ones were masked, to have only
the CDRs available for interaction; in the second one, indicated as
‘blind’ docking, all the MB2.8 residues were considered on an
equal basis, masking only Ab2 CDR residues.
Decoys analysis. The interface in the docking decoys and
the X-ray structure 1DVF [34] (one of the available experimental
Ab1-Ab2 structures) were analyzed, visualized and compared by
the COCOMAPS [30] and CONS-COCOMAPS [29] web tools.
The representative structures of the obtained clusters for each
docking simulation (22 for the CDR-directed and 30 for the ‘blind’
one) were ranked with CONSRANK [31,32]. Finally, a local
structural similarity between the 3D model of Ab2-AIM2 and the
X-ray structure of the original antigen [46,47] of Ab1-MB2.8 was
performed by RASMOT 3D PRO [48], ProBis 2012 [49] and
LGA [50] web tools with default parameters.
Molecular dynamics simulations. The molecular dynam-
ics (MD) simulations were performed using the GROMACS
software (version 4.5.3) [51] with the Amber99SB-ILDN force
field [52]. All systems were slightly relaxed using 50 steps of
steepest descent minimizer. The systems were then immersed in an
explicit water box of TIP3P model [53], which extended at least
10 A˚ away in each direction from any atom of the complex. 20160
and 23094 water molecules were added to the models and to
1DVF, respectively. Ten and three chloride ions were added to the
models and to 1DVF to neutralize the positive charges, as needed
for the particle mesh Ewald calculation [54] of the long-range
electrostatic interactions, while a cut-off of 10 A˚ was used for van
der Waals and short-range electrostatic interactions. 500 steps of
steepest descent minimization were performed to remove bad
contacts with the solvent. All bonds involving hydrogen atoms
were constrained by the LINCS algorithm [55]. Equilibration of
the solvent and ions around the complexes with position
constraints of the heavy atoms was performed for 2 ns in the
NVT ensemble, followed by 2 ns in the NPT ensemble. NVT
simulations were carried out using the velocity rescaling thermo-
stat (V-rescale) [56] and the NPT ones using Parrinello-Rahman
barostat [57]. MD production simulations were performed in the
NPT ensemble for 100-ns for M1-CDR (see below for the models
nomenclature) and 1DVF, and for 20-ns for M2-CDR and M1-
blind. RMSD, gyration radius and energy values were calculated
with standard GROMACS tools. To assess the convergence of the
1DVF and M1-CDR trajectories, we split them into two halves,
and we calculated the root mean square inner product (RMSIP)
between the first 10 eigenvectors of PCA analysis on the two halves
[58,59]. Furthermore, we evaluated the cosine content of the first
10 eigenvectors using the Hess’ approach [60,61].
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Results and Discussion
AIM2 isolation and characterization
In a previous work [27], we have found clear evidence that an
anti-idiotypic response is induced in mice expressing in vivo
antibodies isolated from CD patients directed to TG2 (antibody
MB2.8). In the present work, a phage scFvs library was
constructed from lymphocytes isolated from mouse N.2 that
showed the strongest anti-idiotypic response to the MB2.8
molecule. The scFvs library was then selected against recombinant
MB2.8 antibodies and, after screening, a positive anti-idiotype
clone (AIM2) was identified by phage ELISA. The specificity of
the recognition was confirmed by testing it both as scFv displayed
on phage and as scFv-Fc recombinant antibody against other
antibodies. AIM2 was shown to recognize specifically only MB2.8
(Figure 1b) while it did not bind other TG2-specific antibodies
isolated from CD patients [28] or control antibodies belonging to
the same gene family (VH5). Sequencing of the V genes showed
that the VL chain used the IGKV4-55*01 V region with a CDR3
of 9 amino acids (89–97 definition), while the VH region used the
IGHV1S13*01 with a 8 amino acids long CDR3 sequence (95–
102 definition). AIM2 DNA and protein sequences are reported in
the Supplementary Materials (Sequences S1 and S2 in File S1).
Molecular modeling
Modeling of Ab1-MB2.8 and Ab2-AIM2. To obtain the
structure of the complex between the celiac autoantibody MB2.8
and its anti-idiotype AIM2, by docking simulations, we first
modelled the variable Fab region of the two antibodies with the
RosettaAntibody server [41,42]. Sequence identity with the
templates used to model the framework regions is above 95%
(see Materials and Methods). Modelling of H3 loops, which can be
challenging, is performed by RosettaAntibody de novo, using the
well-known Rosetta fragment-based approach [62]. Extensive
benchmarking showed that it can reliably predict the H3 loop
conformation in most of the cases, but for very long loops (above
17 aa) [63]. Antibody non-H3 CDRs are instead well known to
present a limited number of main-chain conformations, also
named ‘‘Canonical Structures (CSs)’’, based on their length and
the presence of key-residues at specific positions [64]. This makes
the reliable modeling of such regions an easy task, provided that
the right templates are selected. In Table 1, for each CDR, we
report, when applicable, the length, the predicted CS, the PDB ID
of the template used to model it and the length and CS of the
corresponding loop in the template. From Table 1, it is clear that
selected templates share with the CDRs to model length and CS.
The only exception is CDR-L3 in MB2.8. As its sequence fails by
canonical classification, it was modelled based on the structure of
2NY4 CDR-L3, presenting a ‘‘kappa 8’’ CS [65] and sharing with
it the length (11 residues) and the presence of a key proline at
position 95.
It is worth noting here that RosettaAntibody was specifically
developed to obtain highly-refined antibody models, to be also
used in docking simulations, and extensively benchmarking indeed
confirmed the utility of obtained models in docking simulations
[63].
Docking simulations: CDR-directed and ‘blind’. Protein-
protein docking simulations were performed by ClusPro 2.0 [44].
In our ClusPro Ab1-Ab2 simulations, Ab1-MB2.8 acts as the
antigen (i.e. the recognized molecule), while Ab2-AIM2 acts as the
antibody (i.e the recognizing molecule). Therefore, according to
the ClusPro criterions [44], Ab2-AIM2 was fixed and all its
residues not falling into the CDR were masked.
As the experimental data showed that anti-idiotype antibodies
elicited in mouse strongly compete with the original TG2 antigen
for the MB2.8 binding (suggesting that the MB2.8 binding sites for
TG2 and for AIM2 at least partially overlap) [27], in a first set of
simulations (CDR-directed) the non-CDR regions of MB2.8 were
also masked. The 2000 obtained CDR-directed decoys resulted in
22 clusters, with the top-ranked ones highly populated (152 and
118 decoys for the first two clusters, over the total of 2000 decoys
considered). The representative structures for each of the 22
obtained clusters (i.e. the one at the center of the cluster) were
analyzed with the CONS-COCOMAPS [29] server. The consen-
sus map (Figure 2a) showed at a glance the similarity among these
22 docking solutions, since the dark spots converge in defined
Table 1. Length and canonical structure (CS) of the CDRs in the modelled antibodies and in the corresponding templates.
AIM2
loop length predicted-CS template length CS
L1 10 kappa 1 1AY1 10 kappa 1
L2 7 kappa 1 1SEQ 7 kappa 1
L3 9 kappa 1 1AY1 9 kappa 1
H1 5 1 1IQW 5 1
H2 17 2 1IQW 17 2
H3 9 N/A No template N/A N/A
MB2.8
loop length predicted-CS template length CS
L1 11 kappa 2 1DFB 11 kappa 2
L2 7 kappa 1 1DFB 7 kappa 1
L3 11 kappa O 2NY4 11 kappa 8
H1 5 1 2H32 5 1
H2 17 2 2XWT 17 2
H3 12 N/A No template N/A N/A
doi:10.1371/journal.pone.0102839.t001
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regions, located at the crossover of specific CDR loops, mainly
Ab1-MB2.8 L1, L2, L3 and H3 and Ab2-AIM2 L3, H1, H2 and
H3. In Table S1 in File S1, the detailed list of the inter-residue
contacts conserved in at least 25% of the models is reported, as
determined by CONS-COCOMAPS, with the corresponding
conservation rates.
Consistent results were obtained from a second set of ‘blind’
simulations, where Ab1-MB2.8 was not forced to interact through
its CDR residues (i.e., no Ab1-MB2.8 residue was masked during
the docking simulation). Although these ‘blind’ simulations gave
clusters with a lower population, as compared with the CDR-
driven ones (86 vs. 152 decoys for the most populated cluster), they
converged towards a similar binding mode. The representative
models of the ten top-ranked clusters, among the 30 obtained, still
pointed to the CDR region of MB2.8, with the only exception of
one model (ranked 7th according to the cluster population, see
Figure 2d), where Ab2-AIM2 pointed to an Ab1-MB2.8 region
opposite to the CDR. A solution that is not biologically plausible
when the complete antibodies are considered. This was actually
the only obtained model incompatible with the binding of the full
antibody. The similarity between the results from the CDR-driven
and blind simulations was apparent both from the 3D represen-
tation of the 10 top ranked models and from the comparison of the
consensus maps reported in Figure 2. In fact, although the
ensemble of top ranked ‘blind’ solutions presented some additional
spots, the darkest ones still corresponded to those found by the
CDR-driven simulations.
Selection of representative models. ClusPro ranks the
obtained docking solutions based on the population of the
corresponding decoys cluster [44], and the population of a decoys
cluster is indeed commonly used as a criterion to assess the
reliability of a docking solution. For the selection of the most
‘‘promising’’ solutions, in addition, we used CONSRANK, a
consensus method we recently developed for ranking docking
Figure 2. Comparison between the top ‘CDR-directed’ and ‘blind’ docking solutions. (a) and (c): the CONS-COCOMAPS consensus maps
calculated for the 22 models from the CDR-directed docking simulations (a) and for the 30 models from the ‘blind’ ones (c). Labels have been added
for the MB2.8 CDR loops L1-L3 and H1-H3. (b) and (d): Pymol [70] visualization of the representative models of the top ten clusters in both CDR-
directed (c) and ‘blind’ docking simulations (d), after superimposition of Ab1-MB2.8. The MB2.8’s light chain is colored in pink, its heavy chain is
colored in hotpink. All the models using the MB2.8 CDR region for the binding have AIM2 colored in blue, while AIM2 is colored in silver in the 7th
solution of the blind simulation.
doi:10.1371/journal.pone.0102839.g002
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models, based on the conservation of inter-residue contacts in the
decoys ensemble [29,31,32]. In particular, CONSRANK calcu-
lates the conservation rate for each inter-residue contact in a
models ensemble and then ranks models according to their ability
to match the most frequently observed contacts, which can be
regarded as key contacts for the interaction. A very good
performance was found when applying CONSRANK to over
100 docking targets from three different benchmarks [31,32].
Herein, CONSRANK was applied to both the 22 CDR-driven
and 30 blind models separately, and on the ensemble of the 52
CDR-driven and blind models together. Overall, the four top
CONSRANK solutions, when all the 52 ClusPro centroids are
considered, correspond to the ClusPro CDR-driven models 1 and
2 (hereafter M1-CDR and M2-CDR) and to the ‘blind’ models 1
and 3 (M1-blind and M3-blind, see Table 2), thus supporting the
ClusPro population-based ranking. The only discrepancy between
the ClusPro and the CONSRANK analysis concerns M2-blind,
which is ranked low by CONSRANK. The consistency between
the ClusPro clustering analysis and the CONSRANK consensus
analysis indicates that the centroids of the most populated clusters
have an interface that is characterized by the contacts most
frequently observed in the whole set of centroids. In other words,
the most populated cluster is also the one able to better match a
large number of highly-conserved contacts among all the analysed
solutions.
Supported by the convergent ClusPro and CONSRANK
results, we focused our attention on the four top solutions
according to the CONSRANK-all ranking mode. However, since
M2-CDR and M3-blind are extremely similar (the RMSD of the
whole complex being only 0.79 A˚), only M2-CDR was retained
for further analyses, together with M1-CDR and M1-blind. These
three models present a similar binding mode, reflected by the low
values of the RMSD, within <10 A˚, for the backbone superpo-
sition of Ab1-MB2.8, upon best superposition of Ab2-AIM2 (see
Table 3). It is worth reminding here that standard in the docking
field is considering such RMSD values good enough for having
that two structures are a reasonable approximation one of the
other [66,67]. However, the three models clearly differ in the
details of the interaction, such as the number of inter-molecular
H-bonds and of residues at the interface (Table 4). In particular,
Table 2. Top 10 ClusPro models for the CDR-directed and ‘‘blind’’ simulations, with corresponding ClusPro population and ranking
position by CONSRANK.
ClusPro Population CONSRANK-CDR rank CONSRANK-all rank
M1-CDR 152 2 3
M2-CDR 118 1 2
M3-CDR 67 10 8
M4-CDR 65 11 9
M5-CDR 58 9 10
M6-CDR 38 8 5
M7-CDR 38 16 18
M8-CDR 32 13 26
M9-CDR 32 21 31
M10-CDR 32 3 11
ClusPro Population CONSRANK-blind rank CONSRANK-all rank
M1-blind 86 1 4
M2-blind 82 7 16
M3-blind 72 2 1
M4-blind 69 13 38
M5-blind 44 5 20
M6-blind 43 4 23
M7-blind 41 14 43
M8-blind 37 19 41
M9-blind 34 29 49
M10-blind 33 9 34
doi:10.1371/journal.pone.0102839.t002
Table 3. RMSD values calculated on the backbone of Ab1-MB2.8 upon best Ab2-AIM2 superposition.
M1-CDR M2-CDR M1-blind
M1-CDR - 9.2 6.5
M2-CDR - 10.4
M1-blind -
doi:10.1371/journal.pone.0102839.t003
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M1-CDR presents a larger interface (839.6 A˚2) compared to the
other two models, in line with Ab1-Ab2 of known structure (Table
S2 in File S1). Both based on its higher interface area and of its
lower pair-wise Lrmsd_bb values, M1-CDR seems thus to be the
best choice as a representative model for the MB2.8-AIM2
complex.
Detailed analysis of M1-CDR and Comparison with an
Ab1-Ab2 X-ray structure. A detailed analysis of M1-CDR
interface was performed by the COCOMAPS web tool (Table 4).
The complex is stabilized by all six CDRs of both MB2.8 and
AIM2, with the VL of MB2.8 and the VH of AIM2 being
predominant in such contacts. In particular, MB2.8 and AIM2 are
aligned along an ideal axis perpendicular to their CDRs, with the
MB2.8 light chain facing the AIM2 heavy chain and viceversa.
The interface area is 840 A˚2, with a percentage of polar residues at
the interface of approximately 48%.
Both the AIM2 and MB2.8 interfaces involved in the interaction
present a high percentage of hydrophilic residues. Using a cut-off
distance of 5 A˚ to define two atoms in contact, 53 over the total 64
inter-residue contacts occur between two hydrophilic residues.
The complex is also stabilized by a network of 16 hydrogen bonds,
including 4 salt-bridges involving residues Arg31L (loop L1) and
Arg59H (loop H2) of MB2.8 and Asp54H (loop H2) and Arg31L
(loop L1) of MB2.8 (L1) and Asp50L (loop L2), Asp52H and
Asp54H (loop H2) of AIM2. Light and heavy chains of both
antibodies are equally represented in the H-bonds network, with a
slight predominance of the AIM2 heavy chain (participating in 9
H-bonds and 3 salt-bridges). Eleven residues in both AIM2 and
MB2.8 have their accessible surface area (ASA) reduced by more
than 50% upon complex formation (see Table 5 and Figure 3).
These include most of the residues involved in H-bonds and also
several aromatic residues, such as AIM2 Trp33H and MB2.8
Trp32L, involved in a p stacking interaction, AIM2 Trp91L and
MB2.8 Tyr94L, mainly involved in hydrophobic interactions, and
AIM2 Tyr32L, Tyr34L and Tyr94L, giving H-bonds with MB2.8
Ile29L, Asn92L and Arg97L. In Figure 3, all the residues at the
interface, which are more than half buried upon complex
formation, and all those involved in inter-molecular salt bridges
are shown.
Remarkably, the above Ab1-Ab2 binding solution shows a
striking similarity with the binding mode adopted by four of the six
known experimental Ab1-Ab2 structures [14,16,34–37], specifi-
cally with the crystal structures corresponding to the PDB IDs:
1DVF [34], 1PG7 [16], JMB94 (our code, this structure was
published in J Mol Biol in 1994 [35] and never deposited in the
PDB) and, to a smaller extent, 1IAI [36]. 80% of the M1-CDR
heavy atoms can be superimposed to 1DVF, 1PG7 and JMB94
with a RMSD below 5 A˚, and to 1IAI with a RMSD of <7 A˚.
However, the experimental structure most similar to the M1-CDR
model, in terms of RMSD, is 1DVF, a complex between an anti-
hen-egg-white lysozyme antibody, Ab1-D1.3, and its anti-idiotypic
antibody Ab2-E5.2 [34]. 79% of M1-CDR heavy atoms (2756 out
of 3481) can indeed be superimposed to corresponding atoms in
1DVF with an RMSD value of only 3.2 A˚. A detailed comparison
with 1DVF is thus reported in the following. The sequence identity
of the D1.3-E5.2 complex with the MB2.8-AIM2 complex is about
65% for both the L and H chains of the Ab1s and 66% and 48%
for the alignment of the L and H chains, respectively, of the two
Ab2s. In Figure 4, the contact maps of both the MB2.8-AIM2
M1-CDR and the 1DVF crystallographic structure [34] are
reported. From their comparison, it is apparent that the MB2.8-
AIM2 model has similar binding interactions to those in 1DVF. In
fact, both complexes are preferentially stabilized by contacts
between: Ab1 L1, L3 and H2 loops and the light chain of Ab2,
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and Ab1 L1, L2, L3 and H3 loops and the heavy chain of Ab2.
Similar contacts are also observed for the X-ray 1PG7, JMB94
and 1IAI structures, as can be seen from corresponding contact
maps in Figure S1 in File S1, although in 1IAI the interaction
between the Ab1 chain L and Ab2 chain H is less significant. The
interface area of M1-CDR and 1DVF is also very similar (840 A˚2
for the MB2.8-AIM2 and 816 A˚2 for the D1.3-E5.2, see Table 4).
Analogously to the MB2.8-AIM2 complex, in D1.3-E5.2 about
Figure 3. M1-CDR interface. A surface representation of the MB2.8-AIM2 interface in M1-CDR. The MB2.8 light and heavy chains are colored in
pink and hotpink, respectively, while the AIM2 light and heavy chains are colored in lightblue and blue. All residues at the interface that are more
than half buried upon complex formation and all residues involved in inter-molecular salt bridges are shown as sticks and labelled.
doi:10.1371/journal.pone.0102839.g003
Table 5. M1-CDR residues that are more than 50% buried upon complex formation.
AIM2-Ab2 MB2.8-Ab1
Residue Buried ASA (%) Residue Buried ASA (%)
Asp52a_H 98.68 Lys50_L 95.15
Pro52b_H 96.59 Arg31_L 84.59
Asp50_L 86.02 Asp103_H 83.25
Tyr34_L 79.87 Ser93_L 81.08
Trp33_H 76.94 Thr104_H 78.37
Ser31_H 69.35 Tyr94_L 75.50
Trp91_L 69.26 Trp32_L 68.97
Tyr94_L 68.38 Asn92_L 67.17
Ser97_H 67.50 Ile29_L 59.97
Gly96_H 63.66 Ser95_L 58.76
Tyr32_L 58.22 Arg97_L 50.13
doi:10.1371/journal.pone.0102839.t005
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half (46%) of the buried surface upon complex formation is polar,
most of the inter-molecular contacts occur between hydrophilic
residues (43 out of 59) and the complex is stabilized by many inter-
molecular H-bonds (11, including one salt bridge). Overall, 23
residues (9 belonging to E5.2 and 14 to D1.3) have more than 50%
surface buried upon complex formation. They include polar/
charged residues involved in inter-molecular H-bonds, but also
several aromatic residues (see Table S3 in File S1), giving different
types of interaction.
Molecular Dynamics Simulations of M1-CDR. To test the
overall stability of M1-CDR, we performed a 100-ns long
molecular dynamics simulation. For comparison, we performed
a similar simulation for 1DVF Ab1-Ab2 complex [30]. The good
convergence of the simulations is reflected by the high root mean
square inner product (RMSIP) values, 0.77 for M1_CDR and 0.81
for 1DVF, calculated between the first 10 principal component
vectors of the two halves of the trajectories [58,59], and by the low
cosine content of the first 10 principal component vectors (Table
S4 in File S1) [60,61]. Both systems are similarly stable in terms of
the RMSD of the Ca atoms from the starting structure (values
around 2-3 A˚), with marginally higher oscillations for M1-CDR,
see Figure 5 (top). A rather stable behavior is also found when the
focus is on the radius of gyration Rc, a property linked to the
molecular volume and compactness, see Figure 5 (bottom). The
only difference is in an initial marginal fluctuation of the Rc of
M1-CDR from 2.40 to 2.46 nm, which however relaxes to the
initial value along the whole trajectory. This analysis thus indicates
that M1-CDR does not undergo severe conformational rearrange-
ments, and, under dynamic conditions, it behaves similarly to the
1DVF complex. On the other hand, the MD simulations outline
the relative instability of the other top ranked models, M1-blind
and especially M2-CDR. Indeed, for these models the RMSD on
the Ca shows values above 8 and 5 A˚, respectively, within the first
20 ns of simulation, while their gyration radius largely fluctuates,
raising to 2.55–2.60 nm (see Figure S2 in File S1).
Searching for structural similarities between AIM2 (Ab2)
and TG2 (Ag). The last step in the characterization of an Ab1-
Ab2 complex is to identify possible structural similarities between
the anti-idiotype antibody and the original antigen (TG2). As an
experimental structure for the TG2-MB2.8 complex (the corre-
sponding Ag-Ab1 complex) is currently unavailable, we only
searched for a possible local structural similarity between Ab2 and
the original Ab1 antigen TG2. Two web tools used to the aim,
RASMOT 3D PRO [48] and ProBis 2012 [49], were unable to
detect any significant similarity.
However, another web server, LGA, found a significant
structural similarity between the whole TG2 N-terminal domain
(open form [47]) and the AIM2 heavy chain, superimposing the
Figure 4. Comparison between M1-CDR and the X-ray structure of the D1.3-E5.2 Ab1-Ab2 complex (1DVF). (a) and (b): the distance
range contact maps by COCOMAPS [30], calculated for the MB2.8-AIM2 model (a) and the experimental structure of E5.2/D1.3 complex (PDB code:
1DVF) (b). The dots at the crossover of two residues are colored in red, yellow, green and blue if any pair of atom is closer than 7, 10, 13 and 16 A˚,
respectively. (c) and (d): Pymol [70] visualization of MB2.8-AIM2 model (c) and the experimental structure E5.2-D1.3 (d). The color code is the same in
both figures: the Ab1 light and heavy chains are colored in light and dark blues, respectively; the Ab1 light and heavy chains are colored in light and
dark pink, respectively. Labels have been added for the Ab1’s and Ab2’s light and heavy chains.
doi:10.1371/journal.pone.0102839.g004
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Ca atoms of 94 corresponding residues with a RMSD of 2.77 A˚
and a quality score (LGA_S) of 3.27 (2.0 being the threshold for
weak alignments). This is not surprising, as the N-terminal domain
of TG2 is characterized by an Immunoglobulin-like beta-sandwich
fold. In Figure S3 in File S1, the TG2-to-AIM2 structural
correspondence found by LGA is shown, together with the MB2.8-
AIM2 binding mode in M1-CDR. From it, it appears that, in
principle, MB2.8 could bind to the TG2 N-terminal domain,
analogously to how it binds to AIM2, without significant steric
hindrance. However, the composition of the AIM2 (Ab2) CDRs
mainly involved in the MB2.8 binding is quite different from that
of the structurally corresponding TG2 segments. Therefore, even
if this structural correspondence was the basis for a similar binding
mode to the MB2.8 antibody, the anti-idiotype AIM2 antibody
could hardly be described as a molecular mimic of the TG2
antigen.
Conclusions
The high level expression in a mouse model of a cross-reactive
anti-TG2 antibody (MB2.8) leads to a specific and prolonged anti-
idiotypic response [27]. Here we report the isolation and
computational characterization of the interaction between the
celiac anti-TG2 antibody MB2.8 and the anti-idiotype antibody,
AIM2, that was elicited in the mouse model. The specific
monoclonal Ab2 AIM2 was isolated after construction of a scFv
antibody phage library from a mouse showing an anti-idiotypic
immune response to the CD derived MB2.8 antibody and
validated for specificity to the original target.
Molecular modeling simulations were performed on the MB2.8-
AIM2 complex and, as a result, a quite clear picture emerged
about its structural features. The different solutions clearly pointed
to a preferred interface area. The model we selected, M1-CDR, is
very well representative of the different solutions found, at least in
terms of interface contacts. This observation increases our
confidence in the obtained model. Furthermore, an a posteriori
comparison between the selected model and the available
experimental structures of Ab1-Ab2 complexes showed that it is
strikingly similar to most of them, and particularly similar to the
complex between Ab1-D1.3 and Ab2-E5.2 (PDB ID: 1DVF), both
in its static and dynamics features, despite the obvious differences
in sequence. This unexpected result represents, in our opinion, an
independent validation of the obtained model.
Our detailed interface analysis shows that Ab2-AIM2 is directed
against the Ab1-MB2.8 CDR region, especially on VL. This makes
the contemporary formation of the MB2.8-AIM2 (Ab1-Ab2)
complex and of the MB2.8-TG2 complex (Ab1-TG2) incompat-
ible, thus explaining the experimental data showing a strong
inhibitory effect of the anti-idiotype antibodies elicited in mouse on
the MB-2.8 binding to TG2 [27]. The search we performed for
Figure 5. RMSD fluctuation and gyration radius. Top: RMSD fluctuation of the Ca atoms of M1-CDR and 1DVF from the starting geometry
along the 100-ns long MD trajectory. Bottom: Gyration radius, Rc, of M1-CDR and 1DVF along the 100-ns long MD trajectory.
doi:10.1371/journal.pone.0102839.g005
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possible structural similarities between Ab2-AIM2 and original
MB-2.8 antigen, i.e. TG2, detected a structural similarity between
the N-terminal domain of TG2 in its open form and the AIM2
heavy chain. However, the highly different amino acid composi-
tion of the structurally correspondent segments does not allow to
depicting the anti-idiotype AIM2 antibody as a molecular mimic
of the TG2 antigen. Therefore, as AIM2 is an anti-idiotype
antibody which binds the Ab1 (MB2.8) on its antigen-binding site,
without apparently carrying any internal image of the original
antigen (TG2), we suggest its classification as an Ab2c, that is also
the category in which most of the Ab2s having an experimental
structural characterization to date fall [14,16,35,37]).
Due to the crucial involvement of the idiotypic network in the
autoimmune diseases and the promising therapeutic applications,
the detailed model we present for Ab2-AIM2 and for its
interaction with Ab1-MB2.8 could be the basis for new possible
therapeutic strategies, such as the design of humanized antibodies
for the inhibition of TG2 binding by autoantibodies in celiac
disease. Indeed, several experimental evidences have highlighted
the possible pathogenic role of anti-TG2 autoantibodies, as a
consequence of their interaction with TG2 [68,69]. Anti-idiotype
antibodies have already been shown in vivo to be able to down-
regulate autoantibodies, for instance in type-1 diabetes, by
preventing them from binding to the autoantigen [23].
To our knowledge, this is the first report of docking simulations
performed to predict the structure of an Ab1-Ab2 complex. Due to
their complexity and despite their great biomedical interest, this
class of protein complexes has been to date under-characterized
from a structural point of view, both experimentally and
computationally. We proposed here a protocol for the analysis
of docking results, mainly based on the conservation of the
contacts at the interface, which can be applied to the study of both
Ab1-Ab2 and other protein complexes. Furthermore, we hypoth-
esize that the similarity we found between our model and Ab1-
Ab2 experimental structures may be more general and likely also
apply to other Ab1-Ab2 complexes. It could be speculated that,
analogously to the ability of antibodies at recognizing an almost
infinite number of molecules, based on a surprisingly invariant
structural basis [64], also the recognition between antibodies may
be achieved based on a limited set of binding solutions. If
confirmed, this will make the desirable task of modeling antibody-
to-antibody complexes a rather affordable one.
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